TapewireFind a company

person · Reporting owner

Zaks Tal Zvi

Disclosed activity across 3 companies

Tapewire entity
25234
SEC CIK
0001690927

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Adaptimmune Therapeutics PLCADAP · Entity 9824DirectorJuly 01, 2022July 01, 2022
Moderna, Inc.MRNA · Entity 2025Chief Medical OfficerJune 30, 2021July 02, 2021
TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063DirectorAugust 05, 2026August 10, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Adaptimmune Therapeutics PLC

Report date July 01, 2022 · Filed July 01, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Option to purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.28 · Expires 2032-07-01Direct500,000 Reported balance After 2022-07-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2022-07-01 · Grant · Acquired 500,000 · Balance 500,000

F1: The exercise price was converted from GBP0.23 based on an exchange rate of $U.S. 1.216007 to GBP1.00. The actual exercise price will be the pounds sterling amount.

Filing footnotes · ownership attribution and instrument terms

F1: The exercise price was converted from GBP0.23 based on an exchange rate of $U.S. 1.216007 to GBP1.00. The actual exercise price will be the pounds sterling amount.

Moderna, Inc.

Report date June 30, 2021 · Filed July 02, 2021

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Ending reported balance After 2021-06-30 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2021-06-30 · Exercise / conversion · Acquired 5,000 · Balance 5,000

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 5, 2021.

Row 2 · 2021-06-30 · Sale · Disposed 5,000 · Balance 0

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 5, 2021.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.93 · Expires 2030-02-28Direct121,120 Reported balance After 2021-06-30 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2021-06-30 · Exercise / conversion · Disposed 5,000 · Balance 121,120

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 5, 2021.

F2: 25% of this option vested and became exercisable on February 28, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 5, 2021.

F2: 25% of this option vested and became exercisable on February 28, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

TEVA PHARMACEUTICAL INDUSTRIES LTD

Report date August 05, 2026 · Filed August 10, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Ordinary SharesSEC Table I · non-derivativeDirect73,247 Reported balance After 2026-08-05 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-08-05 · Sale · Disposed 17 · Balance 73,247

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Filing footnotes · ownership attribution and instrument terms

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 16, 2020 Filed Jun 18, 2020 22:42 UTC Moderna, Inc. MRNA · Entity 2025 Exercise / conversionCommon Stock 15,631 $19.15 $299,333.65
Disclosure

SEC source: 0001127602-20-020083 · form4.xml · nonDerivative · entry 2

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,752

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

Read SEC document
June 16, 2020 Filed Jun 18, 2020 22:42 UTC Moderna, Inc. MRNA · Entity 2025 Exercise / conversionCommon Stock 24,121 $19.15 $461,917.15
Disclosure

SEC source: 0001127602-20-020083 · form4.xml · nonDerivative · entry 1

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,121

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

Read SEC document
June 09, 2020 Filed Jun 10, 2020 20:28 UTC Moderna, Inc. MRNA · Entity 2025 Exercise / conversionStock Option (Right to Buy) · Derivative 15,631 $0.00 Strike: $19.15 $0.00
Disclosure

SEC source: 0001127602-20-019353 · form4.xml · derivative · entry 6

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 403,798

Underlying: Common Stock · 15,631 shares

Expires 2026-08-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F4 · derivative.exercise_date: This option is fully vested and exercisable.

Read SEC document
June 09, 2020 Filed Jun 10, 2020 20:28 UTC Moderna, Inc. MRNA · Entity 2025 Exercise / conversionStock Option (Right to Buy) · Derivative 24,121 $0.00 Strike: $19.15 $0.00
Disclosure

SEC source: 0001127602-20-019353 · form4.xml · derivative · entry 5

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 419,429

Underlying: Common Stock · 24,121 shares

Expires 2026-08-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F4 · derivative.exercise_date: This option is fully vested and exercisable.

Read SEC document
June 09, 2020 Filed Jun 10, 2020 20:28 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 9,080 $58.95 $535,266.00
Disclosure

SEC source: 0001127602-20-019353 · form4.xml · nonDerivative · entry 4

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.81 to $59.15. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
June 09, 2020 Filed Jun 10, 2020 20:28 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 30,672 $58.33 $1,789,097.76
Disclosure

SEC source: 0001127602-20-019353 · form4.xml · nonDerivative · entry 3

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,080

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.80 to $58.80. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
June 09, 2020 Filed Jun 10, 2020 20:28 UTC Moderna, Inc. MRNA · Entity 2025 Exercise / conversionCommon Stock 15,631 $19.15 $299,333.65
Disclosure

SEC source: 0001127602-20-019353 · form4.xml · nonDerivative · entry 2

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,752

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

Read SEC document
June 09, 2020 Filed Jun 10, 2020 20:28 UTC Moderna, Inc. MRNA · Entity 2025 Exercise / conversionCommon Stock 24,121 $19.15 $461,917.15
Disclosure

SEC source: 0001127602-20-019353 · form4.xml · nonDerivative · entry 1

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,121

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

Read SEC document
June 02, 2020 Filed Jun 4, 2020 22:15 UTC Moderna, Inc. MRNA · Entity 2025 Exercise / conversionStock Option (Right to Buy) · Derivative 39,752 $0.00 Strike: $19.15 $0.00
Disclosure

SEC source: 0001127602-20-018880 · form4.xml · derivative · entry 11

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 443,550

Underlying: Common Stock · 39,752 shares

Expires 2026-08-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F9 · derivative.exercise_date: This option is fully vested and exercisable.

Read SEC document
June 02, 2020 Filed Jun 4, 2020 22:15 UTC Moderna, Inc. MRNA · Entity 2025 Exercise / conversionStock Option (Right to Buy) · Derivative 47,737 $0.00 Strike: $14.22 $0.00
Disclosure

SEC source: 0001127602-20-018880 · form4.xml · derivative · entry 10

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,243

Underlying: Common Stock · 47,737 shares

Expires 2028-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F8 · derivative.exercise_date: 25% of this option vested and became exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter.

Read SEC document
June 02, 2020 Filed Jun 4, 2020 22:15 UTC Moderna, Inc. MRNA · Entity 2025 Exercise / conversionStock Option (Right to Buy) · Derivative 11,467 $0.00 Strike: $12.21 $0.00
Disclosure

SEC source: 0001127602-20-018880 · form4.xml · derivative · entry 9

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,412

Underlying: Common Stock · 11,467 shares

Expires 2027-02-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F7 · derivative.exercise_date: 25% of this option vested and became exercisable on February 22, 2018 with the remainder vesting in 12 equal quarterly installments thereafter.

Read SEC document
June 02, 2020 Filed Jun 4, 2020 22:15 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 4,525 $59.81 $270,640.25
Disclosure

SEC source: 0001127602-20-018880 · form4.xml · nonDerivative · entry 8

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.69 to $59.94. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
June 02, 2020 Filed Jun 4, 2020 22:15 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 30,381 $59.11 $1,795,820.91
Disclosure

SEC source: 0001127602-20-018880 · form4.xml · nonDerivative · entry 7

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,525

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.67 to $59.67. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
June 02, 2020 Filed Jun 4, 2020 22:15 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 48,079 $58.13 $2,794,832.27
Disclosure

SEC source: 0001127602-20-018880 · form4.xml · nonDerivative · entry 6

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,906

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.65 to $58.65. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
June 02, 2020 Filed Jun 4, 2020 22:15 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 12,797 $57.15 $731,348.55
Disclosure

SEC source: 0001127602-20-018880 · form4.xml · nonDerivative · entry 5

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,985

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.61 to $57.61. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
June 02, 2020 Filed Jun 4, 2020 22:15 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 3,174 $56.28 $178,632.72
Disclosure

SEC source: 0001127602-20-018880 · form4.xml · nonDerivative · entry 4

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,782

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.60 to $56.57. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
June 02, 2020 Filed Jun 4, 2020 22:15 UTC Moderna, Inc. MRNA · Entity 2025 Exercise / conversionCommon Stock 39,752 $19.15 $761,250.80
Disclosure

SEC source: 0001127602-20-018880 · form4.xml · nonDerivative · entry 3

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,956

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

Read SEC document
June 02, 2020 Filed Jun 4, 2020 22:15 UTC Moderna, Inc. MRNA · Entity 2025 Exercise / conversionCommon Stock 47,737 $14.22 $678,820.14
Disclosure

SEC source: 0001127602-20-018880 · form4.xml · nonDerivative · entry 2

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,204

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

Read SEC document
June 02, 2020 Filed Jun 4, 2020 22:15 UTC Moderna, Inc. MRNA · Entity 2025 Exercise / conversionCommon Stock 11,467 $12.21 $140,012.07
Disclosure

SEC source: 0001127602-20-018880 · form4.xml · nonDerivative · entry 1

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,467

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

Read SEC document
May 26, 2020 Filed May 28, 2020 22:05 UTC Moderna, Inc. MRNA · Entity 2025 Exercise / conversionStock Option (Right to Buy) · Derivative 42,570 $0.00 Strike: $14.22 $0.00
Disclosure

SEC source: 0001127602-20-018080 · form4.xml · derivative · entry 5

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,980

Underlying: Common Stock · 42,570 shares

Expires 2028-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F3 · derivative.exercise_date: 25% of this option will vest and become exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter.

Read SEC document
May 26, 2020 Filed May 28, 2020 22:05 UTC Moderna, Inc. MRNA · Entity 2025 Exercise / conversionStock Option (Right to Buy) · Derivative 82,474 $0.00 Strike: $12.21 $0.00
Disclosure

SEC source: 0001127602-20-018080 · form4.xml · derivative · entry 4

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 263,760

Underlying: Common Stock · 82,474 shares

Expires 2027-10-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F2 · derivative.exercise_date: 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years).

Read SEC document
May 26, 2020 Filed May 28, 2020 22:05 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 125,044 $66.54 $8,320,427.76
Disclosure

SEC source: 0001127602-20-018080 · form4.xml · nonDerivative · entry 3

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

Read SEC document
May 26, 2020 Filed May 28, 2020 22:05 UTC Moderna, Inc. MRNA · Entity 2025 Exercise / conversionCommon Stock 82,474 $12.21 $1,007,007.54
Disclosure

SEC source: 0001127602-20-018080 · form4.xml · nonDerivative · entry 2

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,044

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

Read SEC document
May 26, 2020 Filed May 28, 2020 22:05 UTC Moderna, Inc. MRNA · Entity 2025 Exercise / conversionCommon Stock 42,570 $14.22 $605,345.40
Disclosure

SEC source: 0001127602-20-018080 · form4.xml · nonDerivative · entry 1

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,570

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

Read SEC document
May 19, 2020 Filed May 20, 2020 20:45 UTC Moderna, Inc. MRNA · Entity 2025 Exercise / conversionStock Option (Right to Buy) · Derivative 112,481 $0.00 Strike: $12.21 $0.00
Disclosure

SEC source: 0001127602-20-017368 · form4.xml · derivative · entry 5

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 346,234

Underlying: Common Stock · 112,481 shares

Expires 2027-10-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F3 · derivative.exercise_date: 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years).

Read SEC document
May 19, 2020 Filed May 20, 2020 20:45 UTC Moderna, Inc. MRNA · Entity 2025 Exercise / conversionStock Option (Right to Buy) · Derivative 12,563 $0.00 Strike: $12.21 $0.00
Disclosure

SEC source: 0001127602-20-017368 · form4.xml · derivative · entry 4

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,879

Underlying: Common Stock · 12,563 shares

Expires 2027-02-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F2 · derivative.exercise_date: 25% of this option vested and became exercisable on February 22, 2018 with the remainder vesting in 12 equal quarterly installments thereafter.

Read SEC document
May 19, 2020 Filed May 20, 2020 20:45 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 125,044 $78.16 $9,773,439.04
Disclosure

SEC source: 0001127602-20-017368 · form4.xml · nonDerivative · entry 3

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
May 19, 2020 Filed May 20, 2020 20:45 UTC Moderna, Inc. MRNA · Entity 2025 Exercise / conversionCommon Stock 112,481 $12.21 $1,373,393.01
Disclosure

SEC source: 0001127602-20-017368 · form4.xml · nonDerivative · entry 2

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,044

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
May 19, 2020 Filed May 20, 2020 20:45 UTC Moderna, Inc. MRNA · Entity 2025 Exercise / conversionCommon Stock 12,563 $12.21 $153,394.23
Disclosure

SEC source: 0001127602-20-017368 · form4.xml · nonDerivative · entry 1

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,563

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
May 19, 2020 Filed Jun 4, 2020 22:51 UTC Amendment Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 125,044 $78.16 $9,773,439.04
Disclosure

SEC source: 0001127602-20-018900 · form4a.xml · nonDerivative · entry 1

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

Read SEC document
May 12, 2020 Filed May 14, 2020 20:56 UTC Moderna, Inc. MRNA · Entity 2025 Exercise / conversionStock Option (Right to Buy) · Derivative 125,044 $0.00 Strike: $12.21 $0.00
Disclosure

SEC source: 0001127602-20-016613 · form4.xml · derivative · entry 8

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,442

Underlying: Common Stock · 125,044 shares

Expires 2027-02-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F8 · derivative.exercise_date: 25% of this option vested and became exercisable on February 22, 2018 with the remainder vesting in 12 equal quarterly installments thereafter.

Read SEC document
May 12, 2020 Filed May 14, 2020 20:56 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 17,744 $62.65 $1,111,661.60
Disclosure

SEC source: 0001127602-20-016613 · form4.xml · nonDerivative · entry 7

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.09 to $63.05. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
May 12, 2020 Filed May 14, 2020 20:56 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 19,817 $63.59 $1,260,163.03
Disclosure

SEC source: 0001127602-20-016613 · form4.xml · nonDerivative · entry 6

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,744

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.10 to $64.10. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
May 12, 2020 Filed May 14, 2020 20:56 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 59,913 $64.72 $3,877,569.36
Disclosure

SEC source: 0001127602-20-016613 · form4.xml · nonDerivative · entry 5

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,561

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.11 to $65.11. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
May 12, 2020 Filed May 14, 2020 20:56 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 25,905 $65.46 $1,695,741.30
Disclosure

SEC source: 0001127602-20-016613 · form4.xml · nonDerivative · entry 4

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,474

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.12 to $66.09. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
May 12, 2020 Filed May 14, 2020 20:56 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 1,365 $66.43 $90,676.95
Disclosure

SEC source: 0001127602-20-016613 · form4.xml · nonDerivative · entry 3

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 123,379

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.13 to $67.11. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
May 12, 2020 Filed May 14, 2020 20:56 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 300 $67.23 $20,169.00
Disclosure

SEC source: 0001127602-20-016613 · form4.xml · nonDerivative · entry 2

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 124,744

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $67.16 to $67.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
May 12, 2020 Filed May 14, 2020 20:56 UTC Moderna, Inc. MRNA · Entity 2025 Exercise / conversionCommon Stock 125,044 $12.21 $1,526,787.24
Disclosure

SEC source: 0001127602-20-016613 · form4.xml · nonDerivative · entry 1

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,044

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
May 05, 2020 Filed May 6, 2020 21:14 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 4,770 $50.48 $240,789.60
Disclosure

SEC source: 0001127602-20-015655 · form4.xml · nonDerivative · entry 1

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
May 05, 2020 Filed Jun 4, 2020 22:53 UTC Amendment Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 4,770 $50.48 $240,789.60
Disclosure

SEC source: 0001127602-20-018902 · form4a.xml · nonDerivative · entry 1

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on September 26, 2019 and January 21, 2020.

Read SEC document
April 24, 2020 Filed Apr 27, 2020 20:12 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 10,000 $47.15 $471,500.00
Disclosure

SEC source: 0001127602-20-014549 · form4.xml · nonDerivative · entry 1

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,770

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
April 17, 2020 Filed Apr 20, 2020 20:37 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 10,000 $48.81 $488,100.00
Disclosure

SEC source: 0001127602-20-014136 · form4.xml · nonDerivative · entry 1

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,770

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
April 13, 2020 Filed Apr 14, 2020 20:17 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 10,000 $32.00 $320,000.00
Disclosure

SEC source: 0001127602-20-013698 · form4.xml · nonDerivative · entry 1

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,770

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
April 03, 2020 Filed Apr 6, 2020 20:10 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 10,000 $32.81 $328,100.00
Disclosure

SEC source: 0001127602-20-013315 · form4.xml · nonDerivative · entry 1

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,770

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
March 27, 2020 Filed Mar 30, 2020 20:13 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 10,000 $28.37 $283,700.00
Disclosure

SEC source: 0001127602-20-012139 · form4.xml · nonDerivative · entry 1

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,770

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
March 20, 2020 Filed Mar 23, 2020 20:13 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 10,000 $29.13 $291,300.00
Disclosure

SEC source: 0001127602-20-011751 · form4.xml · nonDerivative · entry 1

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,770

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
March 13, 2020 Filed Mar 16, 2020 20:24 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 10,000 $23.00 $230,000.00
Disclosure

SEC source: 0001127602-20-010793 · form4.xml · nonDerivative · entry 1

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,770

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
March 06, 2020 Filed Mar 10, 2020 20:24 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 10,000 $27.98 $279,800.00
Disclosure

SEC source: 0001127602-20-010107 · form4.xml · nonDerivative · entry 1

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,770

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
February 28, 2020 Filed Mar 3, 2020 21:35 UTC Moderna, Inc. MRNA · Entity 2025 GrantRestricted Stock Units · Derivative 28,924 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001127602-20-009028 · form4.xml · derivative · entry 3

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,924

Underlying: Common Stock · 28,924 shares

Expires not disclosed

F3 · derivative.exercise_date: 50% of the shares subject to this restricted stock unit award will vest on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter.

F3 · derivative.expiration_date: 50% of the shares subject to this restricted stock unit award will vest on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter.

Read SEC document
February 28, 2020 Filed Mar 3, 2020 21:35 UTC Moderna, Inc. MRNA · Entity 2025 GrantStock Option (Right to Buy) · Derivative 161,120 $0.00 Strike: $25.93 $0.00
Disclosure

SEC source: 0001127602-20-009028 · form4.xml · derivative · entry 2

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 161,120

Underlying: Common Stock · 161,120 shares

Expires 2030-02-28

F2 · derivative.exercise_date: 25% of this option will vest and become exercisable on February 28, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.